Seikagaku Partners with Eisai to Market OA Therapy

Seikagaku entered into an agreement with Eisai to co-develop and market SI-613 sodium hyaluronate in China to treat knee osteoarthritis.

Upon regulatory approval, Eisai will take on distribution. The companies will equally share development costs, and Eisai will pay Seikagaku an upfront payment, along with development and sales milestones.

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us